Definium Therapeutics
DFTX
28.34
-1.14
-3.87%
Definium Therapeutics
US · DFTX
#2132 by market cap
Listed 1970
28.34
-1.14
-3.87%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $78Market Newswire · 2026/9/19
-
Wells Fargo Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $72Market Newswire · 2026/11/12
-
Company notice
Legal Opinion on the First Extraordinary Shareholders' Meeting of Eastern Communications Co., Ltd. in 2024 by Zhejiang Tian Ce Law Firm.SZSI · 2024/8/2
-
Rating change
RBC Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $66Market Newswire · 2026/10/19
-
Rating change
Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $67Market Newswire · 2026/9/16
-
Rating change
A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $70 to $91Market Newswire · 2026/11/10
-
Rating change
BofA Securities Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $91Market Newswire · 2026/10/7
-
Company notice
Mind Medicine: Mind Medicine (MindMed) Inc. - Name/Symbol/CUSIP Change Option Symbol: MNMD New Symbol: DFTXOCC · 2026/1/15
-
Maxim Group Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $55Market Newswire · 2026/11/14
-
JonesTrading Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $90Market Newswire · 2026/11/12
-
Company notice
Oriental Communications: Eastern Communications Co., Ltd. Fund Raising Management System (August 2025)SZSI · 2025/8/29
-
Company notice
Announcement of the resolution of the first extraordinary general meeting of shareholders of Eastern Communications Co., Ltd. in 2024.SZSI · 2024/8/2
-
Rating change
J.P. Morgan Initiates Definium Therapeutics(DFTX.US) With Buy Rating, Announces Target Price $84Market Newswire · 2026/10/9
-
Rating change
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $75Market Newswire · 2026/9/9
-
A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $66 to $78Market Newswire · 2026/11/11
-
Rating change
Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Definium Therapeutics (DFTX)TipRanks · 2026/9/19
-
H.C. Wainwright Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $70Market Newswire · 2026/11/9
-
Rating change
A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $66 to $91Market Newswire · 2026/9/15
-
Rating change
Analysts' Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)TipRanks · 2026/10/7
-
Company notice
Announcement from Eastern Communications Co., Ltd. Regarding the Resignation of Senior Management PersonnelSZSI · 2024/8/27
-
Rating change
BofA Securities Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $75Market Newswire · 2026/8/18
-
Rating change
CCORF Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $64Market Newswire · 2026/9/2
-
Maxim Group Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $55Market Newswire · 2026/9/16
-
Rating change
Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $60Market Newswire · 2026/8/31
-
Rating change
JonesTrading Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $90Market Newswire · 2026/9/15
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:39 · For reference only, not investment advice and not tailored to your situation.
Definium Therapeutics discussion 0 comments